ClinicalTrials.gg
CompletedNCT04233216Updated Dec 27, 2024Results posted

Doravirine/Islatravir (DOR/ISL) in Heavily Treatment-Experienced (HTE) Participants for Human Immunodeficiency Virus Type 1 (HIV-1) Infection (MK-8591A-019)

A Phase 3 interventional study of ISL and DOR in HIV-1 Infection, sponsored by Merck Sharp & Dohme LLC. Completed at 98 sites in 18 countries. Per ClinicalTrials.gov, last updated 2024-12-27.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
35
Allocation
Randomized
Sex
All
01

Study summary

This is a 2-part, phase 3 clinical study evaluating the antiretroviral activity and safety/tolerability of islatravir (ISL), doravirine (DOR), and a fixed dose combination (FDC) of DOR/ISL (also known as MK-8591A) in heavily treatment-experienced (HTE) participants with human immunodeficiency virus type 1 (HIV-1) infection. It is hypothesized that the percentage of participants receiving DOR/ISL to achieve ≥0.5 log10 decrease in HIV-1 ribonucleic acid (RNA) from study baseline (Day 1) to Day 8 is superior to placebo, each given in combination with failing antiretroviral therapy (ART).

Read the detailed description

Part 1 of this study (Day 1 to Day 7) is the double-blind period in which participants receive either ISL, DOR, DOR/ISL, or placebo. Part 2 of this study (Day 8 to Week 97) is the open-label period in which all participants receive DOR/ISL + optimized background therapy (OBT).

02

Conditions studied

  • HIV-1 Infection
03

In context

Lead sponsor

Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.

Of its 503 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Is -1 positive.
  • Has been receiving the same baseline ART for ≥3 months prior to signing the Form/Assent Form.
  • Weighs ≥35 kg.
  • Has at least triple-class resistance (must include nucleoside reverse transcriptase inhibitor [NRTI], non-nucleoside reverse transcriptase inhibitor [NNRTI], and resistance to either protease inhibitor (PI) or integrase strand transfer inhibitor (InSTI), based on central laboratory-based resistance or proviral DNA resistance testing at the Screening Visit, or historical resistance testing within 12 months of screening.
  • Has ≤2 fully active antiretroviral drugs remaining among all antiretroviral classes that can be effectively combined to form a viable regimen based on resistance, tolerability, safety, drug access, or acceptability to participant.
  • If female, is not pregnant or breastfeeding, and is: 1) not a woman of (WOCBP); 2) a WOCBP and uses an acceptable method of /is abstinent; or 3) a WOCBP and has a negative pregnancy test within 24 hours of the first dose of study medication.

Exclusion criteria

Exclusion Criteria:

  • Has type 2 (HIV-2) infection.
  • Has or other to any of the components of the study interventions as determined by the investigator.
  • Has virus (HBV) co-infection (defined as hepatitis B surface antigen [HBsAg]-positive or HBV deoxyribonucleic acid [DNA] positive) and is not currently being treated for HBV.
  • Has a history or current evidence of any condition, therapy (including active TB co-infection), laboratory abnormality or other circumstance (including drug or alcohol abuse or dependence) that might, in the opinion of the investigator, confound the results of the study or interfere with study participation for the full study duration.
  • Is taking or is anticipated to require any of the prohibited therapies from the Screening Visit and throughout the study treatment period.
  • Is taking DOR as part of his/her current failing antiretroviral regimen.
  • Is taking efavirenz (EFV), etravirine, or nevirapine.
  • Is currently participating in or has participated in an interventional clinical study with an compound or device from the Screening Visit through the study treatment period.
  • Is female and is expecting to conceive or donate eggs at any time during the study.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
35 participants (actual)

Study arms

  • Experimental
    ISL + ART

    HTE participants with HIV-1 infection take ISL 0.75 mg once daily (QD) in combination with failing ART from Day 1 to Day 7; followed by open-label 100 mg DOR/0.75 mg ISL fixed dose combination (FDC) QD + OBT from Day 8 to Week 97.

    Drug: ISL · Drug: DOR/ISL

  • Experimental
    DOR + ART

    HTE participants with HIV-1 infection take DOR 100 mg QD in combination with failing ART from Day 1 to Day 7; followed by open-label 100 mg DOR/0.75 mg ISL FDC QD + OBT from Day 8 to Week 97.

    Drug: DOR · Drug: DOR/ISL

  • Experimental
    DOR/ISL + ART

    HTE participants with HIV-1 infection take 100 mg DOR/0.75 mg ISL FDC QD in combination with failing ART from Day 1 to Day 7; followed by open-label 100 mg DOR/0.75 mg ISL FDC QD + OBT from Day 8 to Week 97.

    Drug: DOR/ISL

  • Placebo comparator
    Placebo + ART

    HTE participants with HIV-1 infection take placebo QD in combination with failing ART from Day 1 to Day 7; followed by open-label 100 mg DOR/0.75 mg ISL FDC QD + OBT from Day 8 to Week 97.

    Drug: DOR/ISL · Drug: Placebo to ISL · Drug: Placebo to DOR

Interventions

  • DrugISL

    ISL 0.75 mg capsule taken by mouth.

    Also known as: Islatravir, MK-8591

  • DrugDOR

    DOR 100 mg tablet taken by mouth.

    Also known as: Doravirine, MK-1439

  • DrugDOR/ISL

    Drug pages: Doravirine · Islatravir

    100 mg DOR/0.75 mg ISL FDC taken by mouth.

    Also known as: Doravirine/Islatravir, MK-8591A

  • DrugPlacebo to ISL

    Placebo capsule matched to ISL taken by mouth.

  • DrugPlacebo to DOR

    Placebo tablet matched to DOR taken by mouth.

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Receiving Doravirine/Islatravir (DOR/ISL) With ≥0.5 log10 Change From Day 1 Baseline to Day 8 in Human Immunodeficiency Virus Type 1 (HIV-1) Ribonucleic Acid (RNA) Compared to Placebo Treatment

    Participants with a ≥0.5 log10 decrease from Day 1 baseline to Day 8 in HIV-1 RNA were identified by the central laboratory with an Abbott Real Time Polymerase Chain Reaction (PCR) assay which has a lower limit of detection (LLOD) of 40 copies/mL Only participants treated with DOR/ISL FDC or placebo were analyzed in this outcome measure.

    Time frame: Day 1 (baseline) and Day 8

  2. Percentage of Participants With ≥1 AEs Through Week 49

    An AE is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment.

    Time frame: Up to 49 weeks

  3. Percentage of Participants Withdrawing From Study Treatment Due to AE(s) Through Week 25

    An AE is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment.

    Time frame: Up to 25 weeks

  4. Percentage of Participants With ≥1 Adverse Events (AEs) Through Week 25

    An AE is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment.

    Time frame: Up to 25 weeks

  5. Percentage of Participants Withdrawing From Study Treatment Due to AE(s) Through Week 49

    An AE is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment.

    Time frame: Up to 49 weeks

Secondary outcomes

  1. Percentage of Participants With ≥1 Adverse Events (AEs) Through Week 97

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.

    Time frame: Up to 97 weeks

  2. Percentage of Participants Discontinuing From Study Therapy Due to AE(s) Through Week 97

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.

    Time frame: Up to 97 weeks

  3. Percentage of Participants Receiving DOR or ISL (Given With Antiretroviral Therapy [ART]) With ≥0.5 log10 Change From Day 1 Baseline to Day 8 HIV-1 RNA Compared to Placebo Treatment

    Participants with a ≥0.5 log10 decrease from Day 1 baseline to Day 8 in HIV-1 RNA were identified by the central laboratory with an Abbott Real Time PCR assay which has a LLOD of 40 copies/mL Only participants treated with either DOR or ISL or placebo (given with ART) were analyzed in this outcome measure. Participants treated with DOR/ISL FDC were not analyzed in this outcome measure.

    Time frame: Day 1 (baseline) and Day 8

  4. Mean Change From Baseline Day 1 to Day 8 in HIV-1 RNA Following Treatment With DOR/ISL (Given With ART), DOR, or ISL Compared to Placebo Treatment

    The change from baseline Day to Day 8 in HIV-1 RNA was determined by the central laboratory using an Abbott Real Time PCR assay with a LLOD of 40 copies/mL. The within-group 95% confidence intervals (CIs) were calculated based on the t-distribution.

    Time frame: Day 1 (baseline) and Day 8

  5. Percentage of Participants Receiving DOR/ISL (Given With ART), DOR, or ISL With ≥1.0 log10 Change From Day 1 Baseline to Day 8 HIV-1 RNA Compared to Placebo Treatment

    Participants with a ≥1.0 log10 decrease from baseline (Day 1) to Day 8 in HIV-1 RNA were identified by at the central laboratory with an Abbott Real Time Polymerase Chain Reaction (PCR) assay which has a LLOD of 40 copies/mL

    Time frame: Day 1 (baseline) and Day 8

  6. Percentage of Participants Receiving DOR/ISL (Given With ART) With ≥0.5 log10 Change From Day 1 Baseline to Day 8 in HIV-1 RNA Compared to DOR or ISL Treatment

    Participants with a ≥0.5 log10 decrease from baseline (Day 1) to Day 8 in HIV-1 RNA were identified by at the central laboratory with an Abbott Real Time PCR assay which has a lower limit of detection (LLOD) of 40 copies/mL Only participants treated with DOR/ISL or DOR alone or ISL alone were analyzed in this outcome measure. Participants treated with placebo were not analyzed in this outcome measure.

    Time frame: Day 1 (baseline) and Day 8

  7. Mean Change From Baseline Day 1 to Day 8 in HIV-1 RNA Following Treatment With DOR/ISL (Given With ART) Compared to DOR or ISL Treatment

    The change from baseline Day 1 to Day 8in HIV-1 RNA was determined by the central laboratory using an Abbott Real Time PCR assay with a LLOD of 40 copies/mL. The within-group 95% CIs were calculated based on the t-distribution. The group treated with placebo were not analyzed in this outcome measure.

    Time frame: Day 1 (baseline) and Day 8

  8. Percentage of Participants Receiving DOR/ISL (Given With ART) With ≥1.0 log10 Change From Day 1 Baseline to Day 8 in HIV-1 RNA Compared to DOR or ISL Treatment

    Participants receiving DOR/ISL with a ≥1.0 log10 decrease from baseline (Day 1) to Day 8 in HIV-1 RNA were identified by at the central laboratory with an Abbott Real Time PCR assay which has a lower limit of detection (LLOD) of 40 copies/mL Only participants treated with DOR/ISL or DOR alone or ISL alone were analyzed in this outcome measure. Participants treated with placebo were not analyzed in this outcome measure.

    Time frame: Day 1 (baseline) and Day 8

  9. Percentage of Participants From the Pooled Treatment Group With ≥0.5 log10 Change From Day 1 Baseline to Week 25 in HIV-1 RNA

    The percentage of participants in the pooled treatment group with ≥0.5 log10 change from baseline Day 1 to Week 25 in HIV-1 RNA was determined by the central laboratory using an Abbott Real Time PCR assay with a LLOD of 40 copies/mL. Analysis of the pooled treatment group was planned per protocol,

    Time frame: Day 1 (baseline) and Week 25

  10. Percentage of Participants From the Pooled Treatment Group With ≥0.5 log10 Change From Day 1 Baseline to Week 49 in HIV-1 RNA

    The percentage of participants in the pooled treatment group with ≥0.5 log10 change from baseline Day 1 to Week 49 in HIV-1 RNA was determined by the central laboratory using an Abbott Real Time PCR assay with a LLOD of 40 copies/mL. Analysis of the pooled treatment group was planned per protocol,

    Time frame: Day 1 (baseline) and Week 49

  11. Percentage of Participants From the Pooled Treatment Group With ≥0.5 log10 Change From Day 1 Baseline to Week 97 in HIV-1 RNA

    The percentage of participants in the pooled treatment group with ≥0.5 log10 change from baseline Day 1 to Week 97 in HIV-1 RNA was determined by the central laboratory using an Abbott Real Time PCR assay with a LLOD of 40 copies/mL. Analysis of the pooled treatment group was planned per protocol,

    Time frame: Day 1 (baseline) and Week 97

  12. Percentage of Participants From the Pooled Treatment Group With ≥0.5 log10 Change From Day 8 Baseline to Week 25 in HIV-1 RNA

    The percentage of participants in the pooled treatment group with ≥0.5 log10 change from baseline Day 8 to Week 25 in HIV-1 RNA was determined by the central laboratory using an Abbott Real Time PCR assay with a LLOD of 40 copies/mL. Analysis of the pooled treatment group was planned per protocol,

    Time frame: Day 8 (baseline) and Week 25

  13. Percentage of Participants From the Pooled Treatment Group With ≥0.5 log10 Change From Day 8 Baseline to Week 49 in HIV-1 RNA

    The percentage of participants in the pooled treatment group with ≥0.5 log10 change from baseline Day 8 to Week 49 in HIV-1 RNA was determined by the central laboratory using an Abbott Real Time PCR assay with a LLOD of 40 copies/mL. Analysis of the pooled treatment group was planned per protocol,

    Time frame: Day 8 (baseline) and Week 49

  14. Percentage of Participants From the Pooled Treatment Group With ≥0.5 log10 Change From Day 8 Baseline to Week 97 in HIV-1 RNA

    The percentage of participants in the pooled treatment group with ≥0.5 log10 change from baseline Day 8 to Week 97 in HIV-1 RNA was determined by the central laboratory using an Abbott Real Time PCR assay with a LLOD of 40 copies/mL. Analysis of the pooled treatment group was planned per protocol,

    Time frame: Day 8 (baseline) and Week 97

  15. Percentage of Participants From the Pooled Treatment Group With ≥1.0 log10 Change From Day 1 Baseline to Week 25 in HIV-1 RNA

    The percentage of participants in the pooled treatment group with ≥1.0 log10 change from baseline Day 1 to Week 25 in HIV-1 RNA was determined by the central laboratory using an Abbott Real Time PCR assay with a LLOD of 40 copies/mL. Analysis of the pooled treatment group was planned per protocol,

    Time frame: Day 1 (baseline) and Week 25

  16. Percentage of Participants From the Pooled Treatment Group With ≥1.0 log10 Change From Day 1 Baseline to Week 49 in HIV-1 RNA

    The percentage of participants in the pooled treatment group with ≥1.0 log10 change from baseline Day 1 to Week 49 in HIV-1 RNA was determined by the central laboratory using an Abbott Real Time PCR assay with a LLOD of 40 copies/mL. Analysis of the pooled treatment group was planned per protocol,

    Time frame: Day 1 (baseline) and Week 49

  17. Percentage of Participants From the Pooled Treatment Group With ≥1.0 log10 Change From Day 1 Baseline to Week 97 in HIV-1 RNA

    The percentage of participants in the pooled treatment group with ≥1.0 log10 change from baseline Day 1 to Week 97 in HIV-1 RNA was determined by the central laboratory using an Abbott Real Time PCR assay with a LLOD of 40 copies/mL. Analysis of the pooled treatment group was planned per protocol,

    Time frame: Day 1 (baseline) and Week 97

  18. Percentage of Participants From the Pooled Treatment Group With ≥1.0 log10 Change From Day 8 Baseline to Week 25 in HIV-1 RNA

    The percentage of participants in the pooled treatment group with ≥1.0 log10 change from baseline Day 8 to Week 25 in HIV-1 RNA was determined by the central laboratory using an Abbott Real Time PCR assay with a LLOD of 40 copies/mL. Analysis of the pooled treatment group was planned per protocol,

    Time frame: Day 8 (baseline) and Week 25

  19. Percentage of Participants From the Pooled Treatment Group With ≥1.0 log10 Change From Day 8 Baseline to Week 49 in HIV-1 RNA

    The percentage of participants in the pooled treatment group with ≥1.0 log10 change from baseline Day 8 to Week 49 in HIV-1 RNA was determined by the central laboratory using an Abbott Real Time PCR assay with a LLOD of 40 copies/mL. Analysis of the pooled treatment group was planned per protocol,

    Time frame: Day 8 (baseline) and Week 49

  20. Percentage of Participants From the Pooled Treatment Group With ≥1.0 log10 Change From Day 8 Baseline to Week 97 in HIV-1 RNA

    The percentage of participants in the pooled treatment group with ≥1.0 log10 change from baseline Day 8 to Week 97 in HIV-1 RNA was determined by the central laboratory using an Abbott Real Time PCR assay with a LLOD of 40 copies/mL. Analysis of the pooled treatment group was planned per protocol,

    Time frame: Day 8 (baseline) and Week 97

  21. Mean Change From Baseline Day 1 to Week 25 in HIV-1 RNA From the Pooled Treatment Group

    The change from baseline Day 1 to Week 25 in HIV-1 RNA was determined by the central laboratory using an Abbott Real Time PCR assay with a LLOD of 40 copies/mL. The within-group 95% confidence intervals (CIs) were calculated based on the t-distribution. Analysis of the pooled treatment group was planned per protocol,

    Time frame: Day 1 (baseline) and Week 25

  22. Mean Change From Baseline Day 1 to Week 49 in HIV-1 RNA From the Pooled Treatment Group

    The change from baseline Day 1 to Week 49 in HIV-1 RNA was determined by the central laboratory using an Abbott Real Time PCR assay with a LLOD of 40 copies/mL. The within-group 95% confidence intervals (CIs) were calculated based on the t-distribution. Analysis of the pooled treatment group was planned per protocol,

    Time frame: Day 1 (baseline) and Week 49

  23. Mean Change From Baseline Day 1 to Week 97 in HIV-1 RNA From the Pooled Treatment Group

    The change from baseline Day 1 to Week 97 in HIV-1 RNA was determined by the central laboratory using an Abbott Real Time PCR assay with a LLOD of 40 copies/mL. The within-group 95% confidence intervals (CIs) were calculated based on the t-distribution. Analysis of the pooled treatment group was planned per protocol,

    Time frame: Day 1 (baseline) and Week 97

  24. Mean Change From Baseline Day 8 to Week 25 in HIV-1 RNA From the Pooled Treatment Group

    The change from baseline Day 8 to Week 25 in HIV-1 RNA was determined by the central laboratory using an Abbott Real Time PCR assay with a LLOD of 40 copies/mL. The within-group 95% confidence intervals (CIs) were calculated based on the t-distribution. Analysis of the pooled treatment group was planned per protocol,

    Time frame: Day 8 (baseline) and Week 25

  25. Mean Change From Baseline Day 8 to Week 49 in HIV-1 RNA From the Pooled Treatment Group

    The change from baseline Day 8 to Week 49 in HIV-1 RNA was determined by the central laboratory using an Abbott Real Time PCR assay with a LLOD of 40 copies/mL. The within-group 95% confidence intervals (CIs) were calculated based on the t-distribution. Analysis of the pooled treatment group was planned per protocol,

    Time frame: Day 8 (baseline) and Week 49

  26. Mean Change From Baseline Day 8 to Week 97 in HIV-1 RNA From the Pooled Treatment Group

    The change from baseline Day 8 to Week 97 in HIV-1 RNA was determined by the central laboratory using an Abbott Real Time PCR assay with a LLOD of 40 copies/mL. The within-group 95% confidence intervals (CIs) were calculated based on the t-distribution. Analysis of the pooled treatment group was planned per protocol,

    Time frame: Day 8 (baseline) and Week 97

  27. Percentage of Participants From Day 1 Baseline to Day 8 With HIV-1 RNA <200 Copies mL

    The percentage of participants with HIV-1 RNA \<200 copies mL was determined by the central laboratory using an Abbott Real Time PCR assay with a LLOD of 40 copies/mL. The within-group 95% CIs were calculated based on the Clopper-Pearson method.

    Time frame: Day 1 (baseline) and Day 8

  28. Percentage of Participants From Day 1 Baseline to Day 8 With HIV-1 RNA <50 Copies mL

    The percentage of participants with HIV-1 RNA \<50 copies mL was determined by the central laboratory using an Abbott Real Time PCR assay with a LLOD of 40 copies/mL. The within-group 95% CIs were calculated based on the Clopper-Pearson method.

    Time frame: Day 1 (baseline) and Day 8

  29. Percentage of Participants From Day 1 Baseline to Day 8 With HIV-1 RNA <40 Copies mL

    The percentage of participants with HIV-1 RNA \<40 copies mL was determined by the central laboratory using an Abbott Real Time PCR assay with a LLOD of 40 copies/mL. The within-group 95% CIs were calculated based on the Clopper-Pearson method.

    Time frame: Day 1 (baseline) and Day 8

  30. Percentage of Participants From the Pooled Treatment Group With HIV-1 RNA <200 Copies/mL at Week 25

    The percentage of participants with HIV-1 RNA \<200 copies mL at week 25 was determined by the central laboratory using an Abbott Real Time PCR assay with a LLOD of 40 copies/mL. The within-group 95% CIs were calculated based on the Clopper-Pearson method. Analysis of the pooled treatment group was planned per protocol,

    Time frame: Week 25

  31. Percentage of Participants From the Pooled Treatment Group With HIV-1 RNA <200 Copies/mL at Week 49

    The percentage of participants with HIV-1 RNA \<200 copies mL at week 49 was determined by the central laboratory using an Abbott Real Time PCR assay with a LLOD of 40 copies/mL. The within-group 95% CIs were calculated based on the Clopper-Pearson method. Analysis of the pooled treatment group was planned per protocol,

    Time frame: Week 49

  32. Percentage of Participants From the Pooled Treatment Group With HIV-1 RNA <200 Copies/mL at Week 97

    The percentage of participants with HIV-1 RNA \<200 copies mL at week 97 was determined by the central laboratory using an Abbott Real Time PCR assay with a LLOD of 40 copies/mL. The within-group 95% CIs were calculated based on the Clopper-Pearson method. Analysis of the pooled treatment group was planned per protocol,

    Time frame: Week 97

  33. Percentage of Participants From the Pooled Treatment Group With HIV-1 RNA <50 Copies/mL at Week 25

    The percentage of participants with HIV-1 RNA \<50 copies mL at week 25 was determined by the central laboratory using an Abbott Real Time PCR assay with a LLOD of 40 copies/mL. The within-group 95% CIs were calculated based on the Clopper-Pearson method. Analysis of the pooled treatment group was planned per protocol,

    Time frame: Week 25

  34. Percentage of Participants From the Pooled Treatment Group With HIV-1 RNA <50 Copies/mL at Week 49

    The percentage of participants with HIV-1 RNA \<50 copies mL at week 49 was determined by the central laboratory using an Abbott Real Time PCR assay with a LLOD of 40 copies/mL. The within-group 95% CIs were calculated based on the Clopper-Pearson method. Analysis of the pooled treatment group was planned per protocol,

    Time frame: Week 49

  35. Percentage of Participants From the Pooled Treatment Group With HIV-1 RNA <50 Copies/mL at Week 97

    The percentage of participants with HIV-1 RNA \<50 copies mL at week 97 was determined by the central laboratory using an Abbott Real Time PCR assay with a LLOD of 40 copies/mL. The within-group 95% CIs were calculated based on the Clopper-Pearson method. Analysis of the pooled treatment group was planned per protocol,

    Time frame: Week 97

  36. Percentage of Participants From the Pooled Treatment Group With HIV-1 RNA <40 Copies/mL at Week 25

    The percentage of participants with HIV-1 RNA \<40 copies mL at week 25 was determined by the central laboratory using an Abbott Real Time PCR assay with a LLOD of 40 copies/mL. The within-group 95% CIs were calculated based on the Clopper-Pearson method. Analysis of the pooled treatment group was planned per protocol,

    Time frame: Week 25

  37. Percentage of Participants From the Pooled Treatment Group With HIV-1 RNA <40 Copies/mL at Week 49

    The percentage of participants with HIV-1 RNA \<40 copies mL at week 49 was determined by the central laboratory using an Abbott Real Time PCR assay with a LLOD of 40 copies/mL. The within-group 95% CIs were calculated based on the Clopper-Pearson method. Analysis of the pooled treatment group was planned per protocol.

    Time frame: Week 49

  38. Percentage of Participants From the Pooled Treatment Group With HIV-1 RNA <40 Copies/mL at Week 97

    The percentage of participants with HIV-1 RNA \<40 copies mL at week 97 was determined by the central laboratory using an Abbott Real Time PCR assay with a LLOD of 40 copies/mL. The within-group 95% CIs were calculated based on the Clopper-Pearson method. Analysis of the pooled treatment group was planned per protocol,

    Time frame: Week 97

  39. Percentage of Participants From the Pooled Treatment Group With Treatment-emergent Resistance-associated Substitutions to DOR at Week 25

    The prevalence of viral drug resistance to DOR was based on the percentage of participants with treatment-emergent (TE) resistance-associated substitutions (RASs), which is calculated by dividing the number of participants with TE RASs by the number of participants tested for resistance multiplied by 100. RASs for DOR were as follows: V106A/M, Y188C/L, F227C/H/I/L, M230I/L, L234I, Y318F, V108I, Y188F/H, G190E, H221Y, P236, and were determined by the central laboratory with the GenoSure Prime assay on post randomization samples from participants with HIV-1 RNA ≥200 copies/mL Analysis of the pooled treatment group was planned per protocol.

    Time frame: Week 25

  40. Percentage of Participants From the Pooled Treatment Group With Treatment-emergent Resistance-associated Substitutions to DOR at Week 49

    The prevalence of viral drug resistance to DOR was based on the percentage of participants with TE RASs, which is calculated by dividing the number of participants with TE RASs by the number of participants tested for resistance, multiplied by 100. RASs for DOR were as follows: V106A/M, Y188C/L, F227C/H/I/L, M230I/L, L234I, Y318F, V108I, Y188F/H, G190E, H221Y, P236, and were determined by the central laboratory with the GenoSure Prime assay on post randomization samples from participants with HIV-1 RNA ≥200 copies/mL Analysis of the pooled treatment group was planned per protocol.

    Time frame: Week 49

  41. Percentage of Participants From the Pooled Treatment Group With Treatment-emergent Resistance-associated Substitutions to ISL at Week 25

    The prevalence of viral drug resistance to ISL was based on the percentage of participants with TE RAS, which is calculated by dividing the number of participants with TE RAS by the number of participants tested for resistance, multiplied by 100. The RAS for ISL, M184V was determined by the central laboratory with the GenoSure Prime assay on post randomization samples from participants with HIV-1 RNA ≥200 copies/mL Analysis of the pooled treatment group was planned per protocol.

    Time frame: Week 25

  42. Percentage of Participants From the Pooled Treatment Group With Treatment-emergent Resistance-associated Substitutions to ISL at Week 49

    The prevalence of viral drug resistance to ISL was based on the percentage of participants with TE RAS, which is calculated by dividing the number of participants with TE RAS by the number of participants tested for resistance, multiplied by 100. The RAS for ISL, M184V was determined by the central laboratory with the GenoSure Prime assay on post randomization samples from participants with HIV-1 RNA ≥200 copies/mL Analysis of the pooled treatment group was planned per protocol.

    Time frame: Week 49

  43. Percentage of Participants From the Pooled Treatment Group With Treatment-emergent Resistance-associated Substitutions to Optimized Background Therapy (OBT) Components at Week 25

    The prevalence of viral drug resistance to OBT components was based on the percentage of participants with TE RASs, which is calculated by dividing the number of participants with TE RASs by the number of participants tested for resistance, multiplied by 100. The RASs for OBT components were determined by the central laboratory with the GenoSure Prime assay on post randomization samples from participants with HIV-1 RNA ≥200 copies/mL Analysis of the pooled treatment group was planned per protocol.

    Time frame: Week 25

  44. Percentage of Participants From the Pooled Treatment Group With Treatment-emergent Resistance-associated Substitutions to OBT Components at Week 49

    The prevalence of viral drug resistance to OBT components was based on the percentage of participants with TE RASs, which is calculated by dividing the number of participants with TE RASs by the number of participants tested for resistance, multiplied by 100. The RASs for OBT components were determined by the central laboratory with the GenoSure Prime assay on post randomization samples from participants with HIV-1 RNA ≥200 copies/mL Analysis of the pooled treatment group was planned per protocol.

    Time frame: Week 49

  45. Number of Participants From the Pooled Treatment Group With Viral Resistance-associated Substitutions (RASs) at Week 25

    The number of participants from the pooled treatment group who had HIV-1 RNA ≥200 copies/mL with treatment emergent RAS at week 25 showing the type of RAS .Analysis of the pooled treatment group was planned per protocol,

    Time frame: Week 25

  46. Number of Participants From the Pooled Treatment Group With Viral RASs at Week 49

    The number of participants from the pooled treatment group who had HIV-1 RNA ≥200 copies/mL with treatment emergent RAS at week 49 showing the type of RAS .Analysis of the pooled treatment group was planned per protocol,

    Time frame: Week 49

  47. Number of Participants From the Pooled Treatment Group With Viral RASs at Week 97

    The number of participants from the pooled treatment group with treatment emergent RAS at week 97 are presented, showing the type of RAS .Analysis of the pooled treatment group was planned per protocol,

    Time frame: Week 97

  48. Number of Participants From the Pooled Treatment Group Exhibiting Antiviral Resistance of HIV-1 RNA ≥200 Copies/mL at Week 25

    The number of participants from the pooled treatment group exhibiting antiviral resistance of HIV-1 RNA ≥200 copies/mL at Week 25 is presented. .Analysis of the pooled treatment group was planned per protocol,

    Time frame: Week 25

  49. Number of Participants From the Pooled Treatment Group Exhibiting Antiviral Resistance of HIV-1 RNA ≥200 Copies/mL at Week 49

    The number of participants from the pooled treatment group exhibiting antiviral resistance of HIV-1 RNA ≥200 copies/mL at Week 49 is presented. .Analysis of the pooled treatment group was planned per protocol,

    Time frame: Week 49

  50. Number of Participants From the Pooled Treatment Group Exhibiting Antiviral Resistance of HIV-1 RNA ≥200 Copies/mL at Week 97

    The number of participants from the pooled treatment group exhibiting antiviral resistance of HIV-1 RNA ≥200 copies/mL at Week 97 is presented. .Analysis of the pooled treatment group was planned per protocol,

    Time frame: Week 97

  51. Change From Baseline Day 1 to Week 25 in Cluster of Differentiation 4+ (CD4+) T-cell Counts From the Pooled Treatment Group

    The change from baseline Day 1 to Week 25 in CD4+ T-cell counts was determined by the central laboratory.. The within-group 95% CIs were calculated based on the t-distribution. Analysis of the pooled treatment group was planned per protocol,

    Time frame: Day 1 (baseline) and Week 25

  52. Change From Baseline Day 1 to Week 49 in CD4+ T-cell Counts From the Pooled Treatment Group

    The change from baseline Day 1 to Week 49 in CD4+ T-cell counts was determined by the central laboratory.. The within-group 95% CIs were calculated based on the t-distribution. Analysis of the pooled treatment group was planned per protocol,

    Time frame: Day 1 (baseline) and Week 49

  53. Change From Baseline Day 1 to Week 97 in CD4+ T-cell Counts From the Pooled Treatment Group

    The change from baseline Day 1 to Week 97 in CD4+ T-cell counts was determined by the central laboratory.. The within-group 95% CIs were calculated based on the t-distribution. Analysis of the pooled treatment group was planned per protocol,

    Time frame: Day 1 (baseline) and Week 97

  54. Change From Baseline Day 8 to Week 25 in CD4+ T-cell Counts From the Pooled Treatment Group

    The change from baseline Day 8 to Week 25 in CD4+ T-cell counts was determined by the central laboratory.. The within-group 95% CIs were calculated based on the t-distribution. Analysis of the pooled treatment group was planned per protocol,

    Time frame: Day 8 (baseline) and Week 25

  55. Change From Baseline Day 8 to Week 49 in CD4+ T-cell Counts From the Pooled Treatment Group

    The change from baseline Day 8 to Week 49 in CD4+ T-cell counts was determined by the central laboratory.. The within-group 95% CIs were calculated based on the t-distribution. Analysis of the pooled treatment group was planned per protocol,

    Time frame: Day 8 (baseline) and Week 49

  56. Change From Baseline Day 8 to Week 97 in CD4+ T-cell Counts From the Pooled Treatment Group

    The change from baseline Day 8 to Week 97 in CD4+ T-cell counts was determined by the central laboratory.. The within-group 95% CIs were calculated based on the t-distribution. Analysis of the pooled treatment group was planned per protocol,

    Time frame: Day 8 (baseline) and Week 97

07

Results

Posted Dec 8, 2023

Participant flow

Heavily Treatment-Experienced (HTE) adult participants with Human Immunodeficiency Virus Type 1 (HIV-1) infection and currently on failing antiretroviral therapy (ART) were enrolled in this study.

Participant flow — Overall Study
MilestoneISL + ARTDOR + ARTDOR/ISL + ARTPlacebo + ART
Started71477
Completed6945
Not completed1532
Withdrew: Lost to follow-up1020
Withdrew: Physician decision0302
Withdrew: Withdrawal by subject0210

Outcome measures

PrimaryPercentage of Participants Receiving Doravirine/Islatravir (DOR/ISL) With ≥0.5 log10 Change From Day 1 Baseline to Day 8 in Human Immunodeficiency Virus Type 1 (HIV-1) Ribonucleic Acid (RNA) Compared to Placebo Treatment

Participants with a ≥0.5 log10 decrease from Day 1 baseline to Day 8 in HIV-1 RNA were identified by the central laboratory with an Abbott Real Time Polymerase Chain Reaction (PCR) assay which has a lower limit of detection (LLOD) of 40 copies/mL Only participants treated with DOR/ISL FDC or placebo were analyzed in this outcome measure.

Time frame:
Day 1 (baseline) and Day 8
Reported as:
Number · Percentage of participants
Percentage of Participants Receiving Doravirine/Islatravir (DOR/ISL) With ≥0.5 log10 Change From Day 1 Baseline to Day 8 in Human Immunodeficiency Virus Type 1 (HIV-1) Ribonucleic Acid (RNA) Compared to Placebo Treatment
Percentage of participantsISL + ARTDOR + ARTDOR/ISL + ARTPlacebo + ART
Percentage of Participants Receiving Doravirine/Islatravir (DOR/ISL) With ≥0.5 log10 Change From Day 1 Baseline to Day 8 in Human Immunodeficiency Virus Type 1 (HIV-1) Ribonucleic Acid (RNA) Compared to Placebo Treatment——85.7 (42.1 to 99.6)0.0 (0.0 to 41.0)
PrimaryPercentage of Participants With ≥1 AEs Through Week 49

An AE is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment.

Time frame:
Up to 49 weeks
Reported as:
Number · Percentage of participants
Percentage of Participants With ≥1 AEs Through Week 49
Percentage of participantsISL + ARTDOR + ARTDOR/ISL + ARTPlacebo + ART
Percentage of Participants With ≥1 AEs Through Week 4971.485.785.785.7
PrimaryPercentage of Participants Withdrawing From Study Treatment Due to AE(s) Through Week 25

An AE is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment.

Time frame:
Up to 25 weeks
Reported as:
Number · Percentage of participants
Percentage of Participants Withdrawing From Study Treatment Due to AE(s) Through Week 25
Percentage of participantsISL + ARTDOR + ARTDOR/ISL + ARTPlacebo + ART
Percentage of Participants Withdrawing From Study Treatment Due to AE(s) Through Week 250.07.114.30.0
PrimaryPercentage of Participants With ≥1 Adverse Events (AEs) Through Week 25

An AE is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment.

Time frame:
Up to 25 weeks
Reported as:
Number · Percentage of participants
Percentage of Participants With ≥1 Adverse Events (AEs) Through Week 25
Percentage of participantsISL + ARTDOR + ARTDOR/ISL + ARTPlacebo + ART
Percentage of Participants With ≥1 Adverse Events (AEs) Through Week 2542.985.785.785.7
PrimaryPercentage of Participants Withdrawing From Study Treatment Due to AE(s) Through Week 49

An AE is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment.

Time frame:
Up to 49 weeks
Reported as:
Number · Percentage of participants
Percentage of Participants Withdrawing From Study Treatment Due to AE(s) Through Week 49
Percentage of participantsISL + ARTDOR + ARTDOR/ISL + ARTPlacebo + ART
Percentage of Participants Withdrawing From Study Treatment Due to AE(s) Through Week 490.014.314.30.0
SecondaryPercentage of Participants With ≥1 Adverse Events (AEs) Through Week 97

An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.

Time frame:
Up to 97 weeks
Reported as:
Number · Percentage of participants
Percentage of Participants With ≥1 Adverse Events (AEs) Through Week 97
Percentage of participantsISL + ARTDOR + ARTDOR/ISL + ARTPlacebo + ART
Percentage of Participants With ≥1 Adverse Events (AEs) Through Week 9785.7100.085.7100.0
SecondaryPercentage of Participants Discontinuing From Study Therapy Due to AE(s) Through Week 97

An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.

Time frame:
Up to 97 weeks
Reported as:
Number · Percentage of participants
Percentage of Participants Discontinuing From Study Therapy Due to AE(s) Through Week 97
Percentage of participantsISL + ARTDOR + ARTDOR/ISL + ARTPlacebo + ART
Percentage of Participants Discontinuing From Study Therapy Due to AE(s) Through Week 970.021.428.614.3
SecondaryPercentage of Participants Receiving DOR or ISL (Given With Antiretroviral Therapy [ART]) With ≥0.5 log10 Change From Day 1 Baseline to Day 8 HIV-1 RNA Compared to Placebo Treatment

Participants with a ≥0.5 log10 decrease from Day 1 baseline to Day 8 in HIV-1 RNA were identified by the central laboratory with an Abbott Real Time PCR assay which has a LLOD of 40 copies/mL Only participants treated with either DOR or ISL or placebo (given with ART) were analyzed in this outcome measure. Participants treated with DOR/ISL FDC were not analyzed in this outcome measure.

Time frame:
Day 1 (baseline) and Day 8
Reported as:
Number · Percentage of participants
Percentage of Participants Receiving DOR or ISL (Given With Antiretroviral Therapy [ART]) With ≥0.5 log10 Change From Day 1 Baseline to Day 8 HIV-1 RNA Compared to Placebo Treatment
Percentage of participantsISL + ARTDOR + ARTDOR/ISL + ARTPlacebo + ART
Percentage of Participants Receiving DOR or ISL (Given With Antiretroviral Therapy [ART]) With ≥0.5 log10 Change From Day 1 Baseline to Day 8 HIV-1 RNA Compared to Placebo Treatment28.6 (3.7 to 71.0)78.6 (49.2 to 95.3)—0.0 (0.0 to 41.0)
SecondaryMean Change From Baseline Day 1 to Day 8 in HIV-1 RNA Following Treatment With DOR/ISL (Given With ART), DOR, or ISL Compared to Placebo Treatment

The change from baseline Day to Day 8 in HIV-1 RNA was determined by the central laboratory using an Abbott Real Time PCR assay with a LLOD of 40 copies/mL. The within-group 95% confidence intervals (CIs) were calculated based on the t-distribution.

Time frame:
Day 1 (baseline) and Day 8
Reported as:
Mean · Log10 Copies/mL
Mean Change From Baseline Day 1 to Day 8 in HIV-1 RNA Following Treatment With DOR/ISL (Given With ART), DOR, or ISL Compared to Placebo Treatment
Log10 Copies/mLISL + ARTDOR + ARTDOR/ISL + ARTPlacebo + ART
Mean Change From Baseline Day 1 to Day 8 in HIV-1 RNA Following Treatment With DOR/ISL (Given With ART), DOR, or ISL Compared to Placebo Treatment-0.44 (-0.96 to 0.07)-0.96 (-1.38 to -0.54)-1.23 (-1.72 to -0.75)0.03 (-0.15 to 0.21)
SecondaryPercentage of Participants Receiving DOR/ISL (Given With ART), DOR, or ISL With ≥1.0 log10 Change From Day 1 Baseline to Day 8 HIV-1 RNA Compared to Placebo Treatment

Participants with a ≥1.0 log10 decrease from baseline (Day 1) to Day 8 in HIV-1 RNA were identified by at the central laboratory with an Abbott Real Time Polymerase Chain Reaction (PCR) assay which has a LLOD of 40 copies/mL

Time frame:
Day 1 (baseline) and Day 8
Reported as:
Number · Percentage of participants
Percentage of Participants Receiving DOR/ISL (Given With ART), DOR, or ISL With ≥1.0 log10 Change From Day 1 Baseline to Day 8 HIV-1 RNA Compared to Placebo Treatment
Percentage of participantsISL + ARTDOR + ARTDOR/ISL + ARTPlacebo + ART
Percentage of Participants Receiving DOR/ISL (Given With ART), DOR, or ISL With ≥1.0 log10 Change From Day 1 Baseline to Day 8 HIV-1 RNA Compared to Placebo Treatment14.3 (0.4 to 57.9)50.0 (23.0 to 77.0)85.7 (42.1 to 99.6)0.0 (0.0 to 41.0)
SecondaryPercentage of Participants Receiving DOR/ISL (Given With ART) With ≥0.5 log10 Change From Day 1 Baseline to Day 8 in HIV-1 RNA Compared to DOR or ISL Treatment

Participants with a ≥0.5 log10 decrease from baseline (Day 1) to Day 8 in HIV-1 RNA were identified by at the central laboratory with an Abbott Real Time PCR assay which has a lower limit of detection (LLOD) of 40 copies/mL Only participants treated with DOR/ISL or DOR alone or ISL alone were analyzed in this outcome measure. Participants treated with placebo were not analyzed in this outcome measure.

Time frame:
Day 1 (baseline) and Day 8
Reported as:
Number · Percentage of participants
Percentage of Participants Receiving DOR/ISL (Given With ART) With ≥0.5 log10 Change From Day 1 Baseline to Day 8 in HIV-1 RNA Compared to DOR or ISL Treatment
Percentage of participantsISL + ARTDOR + ARTDOR/ISL + ARTPlacebo + ART
Percentage of Participants Receiving DOR/ISL (Given With ART) With ≥0.5 log10 Change From Day 1 Baseline to Day 8 in HIV-1 RNA Compared to DOR or ISL Treatment28.6 (3.7 to 71.0)78.6 (49.2 to 95.3)85.7 (42.1 to 99.6)—
SecondaryMean Change From Baseline Day 1 to Day 8 in HIV-1 RNA Following Treatment With DOR/ISL (Given With ART) Compared to DOR or ISL Treatment

The change from baseline Day 1 to Day 8in HIV-1 RNA was determined by the central laboratory using an Abbott Real Time PCR assay with a LLOD of 40 copies/mL. The within-group 95% CIs were calculated based on the t-distribution. The group treated with placebo were not analyzed in this outcome measure.

Time frame:
Day 1 (baseline) and Day 8
Reported as:
Mean · Log10 Copies/mL
Mean Change From Baseline Day 1 to Day 8 in HIV-1 RNA Following Treatment With DOR/ISL (Given With ART) Compared to DOR or ISL Treatment
Log10 Copies/mLISL + ARTDOR + ARTDOR/ISL + ARTPlacebo + ART
Mean Change From Baseline Day 1 to Day 8 in HIV-1 RNA Following Treatment With DOR/ISL (Given With ART) Compared to DOR or ISL Treatment-0.44 (-0.96 to 0.07)-0.96 (-1.38 to -0.54)-1.23 (-1.72 to -0.75)—
SecondaryPercentage of Participants Receiving DOR/ISL (Given With ART) With ≥1.0 log10 Change From Day 1 Baseline to Day 8 in HIV-1 RNA Compared to DOR or ISL Treatment

Participants receiving DOR/ISL with a ≥1.0 log10 decrease from baseline (Day 1) to Day 8 in HIV-1 RNA were identified by at the central laboratory with an Abbott Real Time PCR assay which has a lower limit of detection (LLOD) of 40 copies/mL Only participants treated with DOR/ISL or DOR alone or ISL alone were analyzed in this outcome measure. Participants treated with placebo were not analyzed in this outcome measure.

Time frame:
Day 1 (baseline) and Day 8
Reported as:
Number · Percentage of participants
Percentage of Participants Receiving DOR/ISL (Given With ART) With ≥1.0 log10 Change From Day 1 Baseline to Day 8 in HIV-1 RNA Compared to DOR or ISL Treatment
Percentage of participantsISL + ARTDOR + ARTDOR/ISL + ARTPlacebo + ART
Percentage of Participants Receiving DOR/ISL (Given With ART) With ≥1.0 log10 Change From Day 1 Baseline to Day 8 in HIV-1 RNA Compared to DOR or ISL Treatment14.3 (0.4 to 57.9)50.0 (23.0 to 77.0)85.7 (42.1 to 99.6)—
SecondaryPercentage of Participants From the Pooled Treatment Group With ≥0.5 log10 Change From Day 1 Baseline to Week 25 in HIV-1 RNA

The percentage of participants in the pooled treatment group with ≥0.5 log10 change from baseline Day 1 to Week 25 in HIV-1 RNA was determined by the central laboratory using an Abbott Real Time PCR assay with a LLOD of 40 copies/mL. Analysis of the pooled treatment group was planned per protocol,

Time frame:
Day 1 (baseline) and Week 25
Reported as:
Number · Percentage of participants
Percentage of Participants From the Pooled Treatment Group With ≥0.5 log10 Change From Day 1 Baseline to Week 25 in HIV-1 RNA
Percentage of participantsPooled Treatment
Percentage of Participants From the Pooled Treatment Group With ≥0.5 log10 Change From Day 1 Baseline to Week 25 in HIV-1 RNA85.3 (68.9 to 95.0)
SecondaryPercentage of Participants From the Pooled Treatment Group With ≥0.5 log10 Change From Day 1 Baseline to Week 49 in HIV-1 RNA

The percentage of participants in the pooled treatment group with ≥0.5 log10 change from baseline Day 1 to Week 49 in HIV-1 RNA was determined by the central laboratory using an Abbott Real Time PCR assay with a LLOD of 40 copies/mL. Analysis of the pooled treatment group was planned per protocol,

Time frame:
Day 1 (baseline) and Week 49
Reported as:
Number · Percentage of participants
Percentage of Participants From the Pooled Treatment Group With ≥0.5 log10 Change From Day 1 Baseline to Week 49 in HIV-1 RNA
Percentage of participantsPooled Treatment
Percentage of Participants From the Pooled Treatment Group With ≥0.5 log10 Change From Day 1 Baseline to Week 49 in HIV-1 RNA80.6 (62.5 to 92.5)
SecondaryPercentage of Participants From the Pooled Treatment Group With ≥0.5 log10 Change From Day 1 Baseline to Week 97 in HIV-1 RNA

The percentage of participants in the pooled treatment group with ≥0.5 log10 change from baseline Day 1 to Week 97 in HIV-1 RNA was determined by the central laboratory using an Abbott Real Time PCR assay with a LLOD of 40 copies/mL. Analysis of the pooled treatment group was planned per protocol,

Time frame:
Day 1 (baseline) and Week 97
Reported as:
Number · Percentage of participants
Percentage of Participants From the Pooled Treatment Group With ≥0.5 log10 Change From Day 1 Baseline to Week 97 in HIV-1 RNA
Percentage of participantsPooled Treatment
Percentage of Participants From the Pooled Treatment Group With ≥0.5 log10 Change From Day 1 Baseline to Week 97 in HIV-1 RNA84.6 (65.1 to 95.6)
SecondaryPercentage of Participants From the Pooled Treatment Group With ≥0.5 log10 Change From Day 8 Baseline to Week 25 in HIV-1 RNA

The percentage of participants in the pooled treatment group with ≥0.5 log10 change from baseline Day 8 to Week 25 in HIV-1 RNA was determined by the central laboratory using an Abbott Real Time PCR assay with a LLOD of 40 copies/mL. Analysis of the pooled treatment group was planned per protocol,

Time frame:
Day 8 (baseline) and Week 25
Reported as:
Number · Percentage of participants
Percentage of Participants From the Pooled Treatment Group With ≥0.5 log10 Change From Day 8 Baseline to Week 25 in HIV-1 RNA
Percentage of participantsPooled Treatment
Percentage of Participants From the Pooled Treatment Group With ≥0.5 log10 Change From Day 8 Baseline to Week 25 in HIV-1 RNA64.7 (46.5 to 80.3)
SecondaryPercentage of Participants From the Pooled Treatment Group With ≥0.5 log10 Change From Day 8 Baseline to Week 49 in HIV-1 RNA

The percentage of participants in the pooled treatment group with ≥0.5 log10 change from baseline Day 8 to Week 49 in HIV-1 RNA was determined by the central laboratory using an Abbott Real Time PCR assay with a LLOD of 40 copies/mL. Analysis of the pooled treatment group was planned per protocol,

Time frame:
Day 8 (baseline) and Week 49
Reported as:
Number · Percentage of participants
Percentage of Participants From the Pooled Treatment Group With ≥0.5 log10 Change From Day 8 Baseline to Week 49 in HIV-1 RNA
Percentage of participantsPooled Treatment
Percentage of Participants From the Pooled Treatment Group With ≥0.5 log10 Change From Day 8 Baseline to Week 49 in HIV-1 RNA67.7 (48.6 to 83.3)
SecondaryPercentage of Participants From the Pooled Treatment Group With ≥0.5 log10 Change From Day 8 Baseline to Week 97 in HIV-1 RNA

The percentage of participants in the pooled treatment group with ≥0.5 log10 change from baseline Day 8 to Week 97 in HIV-1 RNA was determined by the central laboratory using an Abbott Real Time PCR assay with a LLOD of 40 copies/mL. Analysis of the pooled treatment group was planned per protocol,

Time frame:
Day 8 (baseline) and Week 97
Reported as:
Number · Percentage of participants
Percentage of Participants From the Pooled Treatment Group With ≥0.5 log10 Change From Day 8 Baseline to Week 97 in HIV-1 RNA
Percentage of participantsPooled Treatment
Percentage of Participants From the Pooled Treatment Group With ≥0.5 log10 Change From Day 8 Baseline to Week 97 in HIV-1 RNA69.2 (48.2 to 85.7)
SecondaryPercentage of Participants From the Pooled Treatment Group With ≥1.0 log10 Change From Day 1 Baseline to Week 25 in HIV-1 RNA

The percentage of participants in the pooled treatment group with ≥1.0 log10 change from baseline Day 1 to Week 25 in HIV-1 RNA was determined by the central laboratory using an Abbott Real Time PCR assay with a LLOD of 40 copies/mL. Analysis of the pooled treatment group was planned per protocol,

Time frame:
Day 1 (baseline) and Week 25
Reported as:
Number · Percentage of participants
Percentage of Participants From the Pooled Treatment Group With ≥1.0 log10 Change From Day 1 Baseline to Week 25 in HIV-1 RNA
Percentage of participantsPooled Treatment
Percentage of Participants From the Pooled Treatment Group With ≥1.0 log10 Change From Day 1 Baseline to Week 25 in HIV-1 RNA67.6 (49.5 to 82.6)
SecondaryPercentage of Participants From the Pooled Treatment Group With ≥1.0 log10 Change From Day 1 Baseline to Week 49 in HIV-1 RNA

The percentage of participants in the pooled treatment group with ≥1.0 log10 change from baseline Day 1 to Week 49 in HIV-1 RNA was determined by the central laboratory using an Abbott Real Time PCR assay with a LLOD of 40 copies/mL. Analysis of the pooled treatment group was planned per protocol,

Time frame:
Day 1 (baseline) and Week 49
Reported as:
Number · Percentage of participants
Percentage of Participants From the Pooled Treatment Group With ≥1.0 log10 Change From Day 1 Baseline to Week 49 in HIV-1 RNA
Percentage of participantsPooled Treatment
Percentage of Participants From the Pooled Treatment Group With ≥1.0 log10 Change From Day 1 Baseline to Week 49 in HIV-1 RNA71.0 (52.0 to 85.8)
SecondaryPercentage of Participants From the Pooled Treatment Group With ≥1.0 log10 Change From Day 1 Baseline to Week 97 in HIV-1 RNA

The percentage of participants in the pooled treatment group with ≥1.0 log10 change from baseline Day 1 to Week 97 in HIV-1 RNA was determined by the central laboratory using an Abbott Real Time PCR assay with a LLOD of 40 copies/mL. Analysis of the pooled treatment group was planned per protocol,

Time frame:
Day 1 (baseline) and Week 97
Reported as:
Number · Percentage of participants
Percentage of Participants From the Pooled Treatment Group With ≥1.0 log10 Change From Day 1 Baseline to Week 97 in HIV-1 RNA
Percentage of participantsPooled Treatment
Percentage of Participants From the Pooled Treatment Group With ≥1.0 log10 Change From Day 1 Baseline to Week 97 in HIV-1 RNA73.1 (52.2 to 88.4)
SecondaryPercentage of Participants From the Pooled Treatment Group With ≥1.0 log10 Change From Day 8 Baseline to Week 25 in HIV-1 RNA

The percentage of participants in the pooled treatment group with ≥1.0 log10 change from baseline Day 8 to Week 25 in HIV-1 RNA was determined by the central laboratory using an Abbott Real Time PCR assay with a LLOD of 40 copies/mL. Analysis of the pooled treatment group was planned per protocol,

Time frame:
Day 8 (baseline) and Week 25
Reported as:
Number · Percentage of participants
Percentage of Participants From the Pooled Treatment Group With ≥1.0 log10 Change From Day 8 Baseline to Week 25 in HIV-1 RNA
Percentage of participantsPooled Treatment
Percentage of Participants From the Pooled Treatment Group With ≥1.0 log10 Change From Day 8 Baseline to Week 25 in HIV-1 RNA58.8 (40.7 to 75.4)
SecondaryPercentage of Participants From the Pooled Treatment Group With ≥1.0 log10 Change From Day 8 Baseline to Week 49 in HIV-1 RNA

The percentage of participants in the pooled treatment group with ≥1.0 log10 change from baseline Day 8 to Week 49 in HIV-1 RNA was determined by the central laboratory using an Abbott Real Time PCR assay with a LLOD of 40 copies/mL. Analysis of the pooled treatment group was planned per protocol,

Time frame:
Day 8 (baseline) and Week 49
Reported as:
Number · Percentage of participants
Percentage of Participants From the Pooled Treatment Group With ≥1.0 log10 Change From Day 8 Baseline to Week 49 in HIV-1 RNA
Percentage of participantsPooled Treatment
Percentage of Participants From the Pooled Treatment Group With ≥1.0 log10 Change From Day 8 Baseline to Week 49 in HIV-1 RNA61.3 (42.2 to 78.2)
SecondaryPercentage of Participants From the Pooled Treatment Group With ≥1.0 log10 Change From Day 8 Baseline to Week 97 in HIV-1 RNA

The percentage of participants in the pooled treatment group with ≥1.0 log10 change from baseline Day 8 to Week 97 in HIV-1 RNA was determined by the central laboratory using an Abbott Real Time PCR assay with a LLOD of 40 copies/mL. Analysis of the pooled treatment group was planned per protocol,

Time frame:
Day 8 (baseline) and Week 97
Reported as:
Number · Percentage of participants
Percentage of Participants From the Pooled Treatment Group With ≥1.0 log10 Change From Day 8 Baseline to Week 97 in HIV-1 RNA
Percentage of participantsPooled Treatment
Percentage of Participants From the Pooled Treatment Group With ≥1.0 log10 Change From Day 8 Baseline to Week 97 in HIV-1 RNA61.5 (40.6 to 79.8)
SecondaryMean Change From Baseline Day 1 to Week 25 in HIV-1 RNA From the Pooled Treatment Group

The change from baseline Day 1 to Week 25 in HIV-1 RNA was determined by the central laboratory using an Abbott Real Time PCR assay with a LLOD of 40 copies/mL. The within-group 95% confidence intervals (CIs) were calculated based on the t-distribution. Analysis of the pooled treatment group was planned per protocol,

Time frame:
Day 1 (baseline) and Week 25
Reported as:
Mean · Log10 Copies/mL
Mean Change From Baseline Day 1 to Week 25 in HIV-1 RNA From the Pooled Treatment Group
Log10 Copies/mLPooled Treatment
Mean Change From Baseline Day 1 to Week 25 in HIV-1 RNA From the Pooled Treatment Group-1.89 (-2.33 to -1.45)
SecondaryMean Change From Baseline Day 1 to Week 49 in HIV-1 RNA From the Pooled Treatment Group

The change from baseline Day 1 to Week 49 in HIV-1 RNA was determined by the central laboratory using an Abbott Real Time PCR assay with a LLOD of 40 copies/mL. The within-group 95% confidence intervals (CIs) were calculated based on the t-distribution. Analysis of the pooled treatment group was planned per protocol,

Time frame:
Day 1 (baseline) and Week 49
Reported as:
Mean · Log10 Copies/mL
Mean Change From Baseline Day 1 to Week 49 in HIV-1 RNA From the Pooled Treatment Group
Log10 Copies/mLPooled Treatment
Mean Change From Baseline Day 1 to Week 49 in HIV-1 RNA From the Pooled Treatment Group-2.00 (-2.47 to -1.53)
SecondaryMean Change From Baseline Day 1 to Week 97 in HIV-1 RNA From the Pooled Treatment Group

The change from baseline Day 1 to Week 97 in HIV-1 RNA was determined by the central laboratory using an Abbott Real Time PCR assay with a LLOD of 40 copies/mL. The within-group 95% confidence intervals (CIs) were calculated based on the t-distribution. Analysis of the pooled treatment group was planned per protocol,

Time frame:
Day 1 (baseline) and Week 97
Reported as:
Mean · Log10 Copies/mL
Mean Change From Baseline Day 1 to Week 97 in HIV-1 RNA From the Pooled Treatment Group
Log10 Copies/mLPooled Treatment
Mean Change From Baseline Day 1 to Week 97 in HIV-1 RNA From the Pooled Treatment Group-2.01 (-2.51 to -1.52)
SecondaryMean Change From Baseline Day 8 to Week 25 in HIV-1 RNA From the Pooled Treatment Group

The change from baseline Day 8 to Week 25 in HIV-1 RNA was determined by the central laboratory using an Abbott Real Time PCR assay with a LLOD of 40 copies/mL. The within-group 95% confidence intervals (CIs) were calculated based on the t-distribution. Analysis of the pooled treatment group was planned per protocol,

Time frame:
Day 8 (baseline) and Week 25
Reported as:
Mean · Log10 Copies/mL
Mean Change From Baseline Day 8 to Week 25 in HIV-1 RNA From the Pooled Treatment Group
Log10 Copies/mLPooled Treatment
Mean Change From Baseline Day 8 to Week 25 in HIV-1 RNA From the Pooled Treatment Group-1.16 (-1.56 to -0.77)
SecondaryMean Change From Baseline Day 8 to Week 49 in HIV-1 RNA From the Pooled Treatment Group

The change from baseline Day 8 to Week 49 in HIV-1 RNA was determined by the central laboratory using an Abbott Real Time PCR assay with a LLOD of 40 copies/mL. The within-group 95% confidence intervals (CIs) were calculated based on the t-distribution. Analysis of the pooled treatment group was planned per protocol,

Time frame:
Day 8 (baseline) and Week 49
Reported as:
Mean · Log10 Copies/mL
Mean Change From Baseline Day 8 to Week 49 in HIV-1 RNA From the Pooled Treatment Group
Log10 Copies/mLPooled Treatment
Mean Change From Baseline Day 8 to Week 49 in HIV-1 RNA From the Pooled Treatment Group-1.32 (-1.72 to -0.91)
SecondaryMean Change From Baseline Day 8 to Week 97 in HIV-1 RNA From the Pooled Treatment Group

The change from baseline Day 8 to Week 97 in HIV-1 RNA was determined by the central laboratory using an Abbott Real Time PCR assay with a LLOD of 40 copies/mL. The within-group 95% confidence intervals (CIs) were calculated based on the t-distribution. Analysis of the pooled treatment group was planned per protocol,

Time frame:
Day 8 (baseline) and Week 97
Reported as:
Mean · Log10 Copies/mL
Mean Change From Baseline Day 8 to Week 97 in HIV-1 RNA From the Pooled Treatment Group
Log10 Copies/mLPooled Treatment
Mean Change From Baseline Day 8 to Week 97 in HIV-1 RNA From the Pooled Treatment Group-1.36 (-1.83 to -0.89)
SecondaryPercentage of Participants From Day 1 Baseline to Day 8 With HIV-1 RNA <200 Copies mL

The percentage of participants with HIV-1 RNA \<200 copies mL was determined by the central laboratory using an Abbott Real Time PCR assay with a LLOD of 40 copies/mL. The within-group 95% CIs were calculated based on the Clopper-Pearson method.

Time frame:
Day 1 (baseline) and Day 8
Reported as:
Number · Percentage of participants
Percentage of Participants From Day 1 Baseline to Day 8 With HIV-1 RNA <200 Copies mL
Percentage of participantsISL + ARTDOR + ARTDOR/ISL + ARTPlacebo + ART
Day 10.0 (0.0 to 41.0)0.0 (0.0 to 23.2)0.0 (0.0 to 41.0)0.0 (0.0 to 41.0)
Day 80.0 (0.0 to 41.0)14.3 (1.8 to 42.8)14.3 (0.4 to 57.9)0.0 (0.0 to 41.0)
SecondaryPercentage of Participants From Day 1 Baseline to Day 8 With HIV-1 RNA <50 Copies mL

The percentage of participants with HIV-1 RNA \<50 copies mL was determined by the central laboratory using an Abbott Real Time PCR assay with a LLOD of 40 copies/mL. The within-group 95% CIs were calculated based on the Clopper-Pearson method.

Time frame:
Day 1 (baseline) and Day 8
Reported as:
Number · Percentage of participants
Percentage of Participants From Day 1 Baseline to Day 8 With HIV-1 RNA <50 Copies mL
Percentage of participantsISL + ARTDOR + ARTDOR/ISL + ARTPlacebo + ART
Day 10.0 (0.0 to 41.0)0.0 (0.0 to 23.2)0.0 (0.0 to 41.0)0.0 (0.0 to 41.0)
Day 80.0 (0.0 to 41.0)14.3 (1.8 to 42.8)0.0 (0.0 to 41.0)0.0 (0.0 to 41.0)
SecondaryPercentage of Participants From Day 1 Baseline to Day 8 With HIV-1 RNA <40 Copies mL

The percentage of participants with HIV-1 RNA \<40 copies mL was determined by the central laboratory using an Abbott Real Time PCR assay with a LLOD of 40 copies/mL. The within-group 95% CIs were calculated based on the Clopper-Pearson method.

Time frame:
Day 1 (baseline) and Day 8
Reported as:
Number · Percentage of participants
Percentage of Participants From Day 1 Baseline to Day 8 With HIV-1 RNA <40 Copies mL
Percentage of participantsISL + ARTDOR + ARTDOR/ISL + ARTPlacebo + ART
Day 10.0 (0.0 to 41.0)0.0 (0.0 to 23.2)0.0 (0.0 to 41.0)0.0 (0.0 to 41.0)
Day 80.0 (0.0 to 41.0)14.3 (1.8 to 42.8)0.0 (0.0 to 41.0)0.0 (0.0 to 41.0)
SecondaryPercentage of Participants From the Pooled Treatment Group With HIV-1 RNA <200 Copies/mL at Week 25

The percentage of participants with HIV-1 RNA \<200 copies mL at week 25 was determined by the central laboratory using an Abbott Real Time PCR assay with a LLOD of 40 copies/mL. The within-group 95% CIs were calculated based on the Clopper-Pearson method. Analysis of the pooled treatment group was planned per protocol,

Time frame:
Week 25
Reported as:
Number · Percentage of participants
Percentage of Participants From the Pooled Treatment Group With HIV-1 RNA <200 Copies/mL at Week 25
Percentage of participantsPooled Treatment
Percentage of Participants From the Pooled Treatment Group With HIV-1 RNA <200 Copies/mL at Week 2564.7 (46.5 to 80.3)
SecondaryPercentage of Participants From the Pooled Treatment Group With HIV-1 RNA <200 Copies/mL at Week 49

The percentage of participants with HIV-1 RNA \<200 copies mL at week 49 was determined by the central laboratory using an Abbott Real Time PCR assay with a LLOD of 40 copies/mL. The within-group 95% CIs were calculated based on the Clopper-Pearson method. Analysis of the pooled treatment group was planned per protocol,

Time frame:
Week 49
Reported as:
Number · Percentage of participants
Percentage of Participants From the Pooled Treatment Group With HIV-1 RNA <200 Copies/mL at Week 49
Percentage of participantsPooled Treatment
Percentage of Participants From the Pooled Treatment Group With HIV-1 RNA <200 Copies/mL at Week 4977.4 (58.9 to 90.4)
SecondaryPercentage of Participants From the Pooled Treatment Group With HIV-1 RNA <200 Copies/mL at Week 97

The percentage of participants with HIV-1 RNA \<200 copies mL at week 97 was determined by the central laboratory using an Abbott Real Time PCR assay with a LLOD of 40 copies/mL. The within-group 95% CIs were calculated based on the Clopper-Pearson method. Analysis of the pooled treatment group was planned per protocol,

Time frame:
Week 97
Reported as:
Number · Percentage of participants
Percentage of Participants From the Pooled Treatment Group With HIV-1 RNA <200 Copies/mL at Week 97
Percentage of participantsPooled Treatment
Percentage of Participants From the Pooled Treatment Group With HIV-1 RNA <200 Copies/mL at Week 9780.8 (60.6 to 93.4)
SecondaryPercentage of Participants From the Pooled Treatment Group With HIV-1 RNA <50 Copies/mL at Week 25

The percentage of participants with HIV-1 RNA \<50 copies mL at week 25 was determined by the central laboratory using an Abbott Real Time PCR assay with a LLOD of 40 copies/mL. The within-group 95% CIs were calculated based on the Clopper-Pearson method. Analysis of the pooled treatment group was planned per protocol,

Time frame:
Week 25
Reported as:
Number · Percentage of participants
Percentage of Participants From the Pooled Treatment Group With HIV-1 RNA <50 Copies/mL at Week 25
Percentage of participantsPooled Treatment
Percentage of Participants From the Pooled Treatment Group With HIV-1 RNA <50 Copies/mL at Week 2558.8 (40.7 to 75.4)
SecondaryPercentage of Participants From the Pooled Treatment Group With HIV-1 RNA <50 Copies/mL at Week 49

The percentage of participants with HIV-1 RNA \<50 copies mL at week 49 was determined by the central laboratory using an Abbott Real Time PCR assay with a LLOD of 40 copies/mL. The within-group 95% CIs were calculated based on the Clopper-Pearson method. Analysis of the pooled treatment group was planned per protocol,

Time frame:
Week 49
Reported as:
Number · Percentage of participants
Percentage of Participants From the Pooled Treatment Group With HIV-1 RNA <50 Copies/mL at Week 49
Percentage of participantsPooled Treatment
Percentage of Participants From the Pooled Treatment Group With HIV-1 RNA <50 Copies/mL at Week 4971.0 (52.0 to 85.8)
SecondaryPercentage of Participants From the Pooled Treatment Group With HIV-1 RNA <50 Copies/mL at Week 97

The percentage of participants with HIV-1 RNA \<50 copies mL at week 97 was determined by the central laboratory using an Abbott Real Time PCR assay with a LLOD of 40 copies/mL. The within-group 95% CIs were calculated based on the Clopper-Pearson method. Analysis of the pooled treatment group was planned per protocol,

Time frame:
Week 97
Reported as:
Number · Percentage of participants
Percentage of Participants From the Pooled Treatment Group With HIV-1 RNA <50 Copies/mL at Week 97
Percentage of participantsPooled Treatment
Percentage of Participants From the Pooled Treatment Group With HIV-1 RNA <50 Copies/mL at Week 9769.2 (48.2 to 85.7)
SecondaryPercentage of Participants From the Pooled Treatment Group With HIV-1 RNA <40 Copies/mL at Week 25

The percentage of participants with HIV-1 RNA \<40 copies mL at week 25 was determined by the central laboratory using an Abbott Real Time PCR assay with a LLOD of 40 copies/mL. The within-group 95% CIs were calculated based on the Clopper-Pearson method. Analysis of the pooled treatment group was planned per protocol,

Time frame:
Week 25
Reported as:
Number · Percentage of participants
Percentage of Participants From the Pooled Treatment Group With HIV-1 RNA <40 Copies/mL at Week 25
Percentage of participantsPooled Treatment
Percentage of Participants From the Pooled Treatment Group With HIV-1 RNA <40 Copies/mL at Week 2558.8 (40.7 to 75.4)
SecondaryPercentage of Participants From the Pooled Treatment Group With HIV-1 RNA <40 Copies/mL at Week 49

The percentage of participants with HIV-1 RNA \<40 copies mL at week 49 was determined by the central laboratory using an Abbott Real Time PCR assay with a LLOD of 40 copies/mL. The within-group 95% CIs were calculated based on the Clopper-Pearson method. Analysis of the pooled treatment group was planned per protocol.

Time frame:
Week 49
Reported as:
Number · Percentage of participants
Percentage of Participants From the Pooled Treatment Group With HIV-1 RNA <40 Copies/mL at Week 49
Percentage of participantsPooled Treatment
Percentage of Participants From the Pooled Treatment Group With HIV-1 RNA <40 Copies/mL at Week 4971.0 (52.0 to 85.8)
SecondaryPercentage of Participants From the Pooled Treatment Group With HIV-1 RNA <40 Copies/mL at Week 97

The percentage of participants with HIV-1 RNA \<40 copies mL at week 97 was determined by the central laboratory using an Abbott Real Time PCR assay with a LLOD of 40 copies/mL. The within-group 95% CIs were calculated based on the Clopper-Pearson method. Analysis of the pooled treatment group was planned per protocol,

Time frame:
Week 97
Reported as:
Number · Percentage of participants
Percentage of Participants From the Pooled Treatment Group With HIV-1 RNA <40 Copies/mL at Week 97
Percentage of participantsPooled Treatment
Percentage of Participants From the Pooled Treatment Group With HIV-1 RNA <40 Copies/mL at Week 9769.2 (48.2 to 85.7)
SecondaryPercentage of Participants From the Pooled Treatment Group With Treatment-emergent Resistance-associated Substitutions to DOR at Week 25

The prevalence of viral drug resistance to DOR was based on the percentage of participants with treatment-emergent (TE) resistance-associated substitutions (RASs), which is calculated by dividing the number of participants with TE RASs by the number of participants tested for resistance multiplied by 100. RASs for DOR were as follows: V106A/M, Y188C/L, F227C/H/I/L, M230I/L, L234I, Y318F, V108I, Y188F/H, G190E, H221Y, P236, and were determined by the central laboratory with the GenoSure Prime assay on post randomization samples from participants with HIV-1 RNA ≥200 copies/mL Analysis of the pooled treatment group was planned per protocol.

Time frame:
Week 25
Reported as:
Number · Percentage of participants
Percentage of Participants From the Pooled Treatment Group With Treatment-emergent Resistance-associated Substitutions to DOR at Week 25
Percentage of participantsPooled Treatment
Percentage of Participants From the Pooled Treatment Group With Treatment-emergent Resistance-associated Substitutions to DOR at Week 2533.3
SecondaryPercentage of Participants From the Pooled Treatment Group With Treatment-emergent Resistance-associated Substitutions to DOR at Week 49

The prevalence of viral drug resistance to DOR was based on the percentage of participants with TE RASs, which is calculated by dividing the number of participants with TE RASs by the number of participants tested for resistance, multiplied by 100. RASs for DOR were as follows: V106A/M, Y188C/L, F227C/H/I/L, M230I/L, L234I, Y318F, V108I, Y188F/H, G190E, H221Y, P236, and were determined by the central laboratory with the GenoSure Prime assay on post randomization samples from participants with HIV-1 RNA ≥200 copies/mL Analysis of the pooled treatment group was planned per protocol.

Time frame:
Week 49
Reported as:
Number · Percentage of participants
Percentage of Participants From the Pooled Treatment Group With Treatment-emergent Resistance-associated Substitutions to DOR at Week 49
Percentage of participantsPooled Treatment
Percentage of Participants From the Pooled Treatment Group With Treatment-emergent Resistance-associated Substitutions to DOR at Week 4928.6
SecondaryPercentage of Participants From the Pooled Treatment Group With Treatment-emergent Resistance-associated Substitutions to ISL at Week 25

The prevalence of viral drug resistance to ISL was based on the percentage of participants with TE RAS, which is calculated by dividing the number of participants with TE RAS by the number of participants tested for resistance, multiplied by 100. The RAS for ISL, M184V was determined by the central laboratory with the GenoSure Prime assay on post randomization samples from participants with HIV-1 RNA ≥200 copies/mL Analysis of the pooled treatment group was planned per protocol.

Time frame:
Week 25
Reported as:
Number · Percentage of participants
Percentage of Participants From the Pooled Treatment Group With Treatment-emergent Resistance-associated Substitutions to ISL at Week 25
Percentage of participantsPooled Treatment
Percentage of Participants From the Pooled Treatment Group With Treatment-emergent Resistance-associated Substitutions to ISL at Week 258.3
SecondaryPercentage of Participants From the Pooled Treatment Group With Treatment-emergent Resistance-associated Substitutions to ISL at Week 49

The prevalence of viral drug resistance to ISL was based on the percentage of participants with TE RAS, which is calculated by dividing the number of participants with TE RAS by the number of participants tested for resistance, multiplied by 100. The RAS for ISL, M184V was determined by the central laboratory with the GenoSure Prime assay on post randomization samples from participants with HIV-1 RNA ≥200 copies/mL Analysis of the pooled treatment group was planned per protocol.

Time frame:
Week 49
Reported as:
Number · Percentage of participants
Percentage of Participants From the Pooled Treatment Group With Treatment-emergent Resistance-associated Substitutions to ISL at Week 49
Percentage of participantsPooled Treatment
Percentage of Participants From the Pooled Treatment Group With Treatment-emergent Resistance-associated Substitutions to ISL at Week 4914.3
SecondaryPercentage of Participants From the Pooled Treatment Group With Treatment-emergent Resistance-associated Substitutions to Optimized Background Therapy (OBT) Components at Week 25

The prevalence of viral drug resistance to OBT components was based on the percentage of participants with TE RASs, which is calculated by dividing the number of participants with TE RASs by the number of participants tested for resistance, multiplied by 100. The RASs for OBT components were determined by the central laboratory with the GenoSure Prime assay on post randomization samples from participants with HIV-1 RNA ≥200 copies/mL Analysis of the pooled treatment group was planned per protocol.

Time frame:
Week 25
Reported as:
Number · Percentage of participants
Percentage of Participants From the Pooled Treatment Group With Treatment-emergent Resistance-associated Substitutions to Optimized Background Therapy (OBT) Components at Week 25
Percentage of participantsPooled Treatment
Percentage of Participants From the Pooled Treatment Group With Treatment-emergent Resistance-associated Substitutions to Optimized Background Therapy (OBT) Components at Week 2525.0
SecondaryPercentage of Participants From the Pooled Treatment Group With Treatment-emergent Resistance-associated Substitutions to OBT Components at Week 49

The prevalence of viral drug resistance to OBT components was based on the percentage of participants with TE RASs, which is calculated by dividing the number of participants with TE RASs by the number of participants tested for resistance, multiplied by 100. The RASs for OBT components were determined by the central laboratory with the GenoSure Prime assay on post randomization samples from participants with HIV-1 RNA ≥200 copies/mL Analysis of the pooled treatment group was planned per protocol.

Time frame:
Week 49
Reported as:
Number · Percentage of participants
Percentage of Participants From the Pooled Treatment Group With Treatment-emergent Resistance-associated Substitutions to OBT Components at Week 49
Percentage of participantsPooled Treatment
Percentage of Participants From the Pooled Treatment Group With Treatment-emergent Resistance-associated Substitutions to OBT Components at Week 4928.6
SecondaryNumber of Participants From the Pooled Treatment Group With Viral Resistance-associated Substitutions (RASs) at Week 25

The number of participants from the pooled treatment group who had HIV-1 RNA ≥200 copies/mL with treatment emergent RAS at week 25 showing the type of RAS .Analysis of the pooled treatment group was planned per protocol,

Time frame:
Week 25
Reported as:
Count of participants · Participants
Number of Participants From the Pooled Treatment Group With Viral Resistance-associated Substitutions (RASs) at Week 25
ParticipantsPooled Treatment
RAS A98G2
RAS D67N1
RAS H221Y1
RAS K103S1
RAS K219E1
RAS L234I1
RAS M184V1
RAS M41L1
RAS N348I1
RAS V106A3
RAS V106I2
RAS V106M1
RAS V179I2
RAS Y318F1
RAS F53L1
RAS L90M1
RAS M36I1
SecondaryNumber of Participants From the Pooled Treatment Group With Viral RASs at Week 49

The number of participants from the pooled treatment group who had HIV-1 RNA ≥200 copies/mL with treatment emergent RAS at week 49 showing the type of RAS .Analysis of the pooled treatment group was planned per protocol,

Time frame:
Week 49
Reported as:
Count of participants · Participants
Number of Participants From the Pooled Treatment Group With Viral RASs at Week 49
ParticipantsPooled Treatment
RAS A98G1
RAS D67N1
RAS K103S1
RAS K219E1
RAS M184V1
RAS M41L1
RAS N348I1
RAS V106A2
RAS V106I1
RAS V106M1
RAS V179I2
RAS F53L1
RAS L90M1
RAS M36I1
SecondaryNumber of Participants From the Pooled Treatment Group With Viral RASs at Week 97

The number of participants from the pooled treatment group with treatment emergent RAS at week 97 are presented, showing the type of RAS .Analysis of the pooled treatment group was planned per protocol,

Time frame:
Week 97
Reported as:
Count of participants · Participants
Number of Participants From the Pooled Treatment Group With Viral RASs at Week 97
ParticipantsPooled Treatment
RAS D67N1
RAS M41L1
RAS N348I1
RAS T215F1
RAS V106A2
RAS V106I1
RAS V106M1
RAS V179I1
RAS F53L1
RAS L90M1
RAS M36I1
SecondaryNumber of Participants From the Pooled Treatment Group Exhibiting Antiviral Resistance of HIV-1 RNA ≥200 Copies/mL at Week 25

The number of participants from the pooled treatment group exhibiting antiviral resistance of HIV-1 RNA ≥200 copies/mL at Week 25 is presented. .Analysis of the pooled treatment group was planned per protocol,

Time frame:
Week 25
Reported as:
Count of participants · Participants
Number of Participants From the Pooled Treatment Group Exhibiting Antiviral Resistance of HIV-1 RNA ≥200 Copies/mL at Week 25
ParticipantsPooled Treatment
Number of Participants From the Pooled Treatment Group Exhibiting Antiviral Resistance of HIV-1 RNA ≥200 Copies/mL at Week 2512
SecondaryNumber of Participants From the Pooled Treatment Group Exhibiting Antiviral Resistance of HIV-1 RNA ≥200 Copies/mL at Week 49

The number of participants from the pooled treatment group exhibiting antiviral resistance of HIV-1 RNA ≥200 copies/mL at Week 49 is presented. .Analysis of the pooled treatment group was planned per protocol,

Time frame:
Week 49
Reported as:
Count of participants · Participants
Number of Participants From the Pooled Treatment Group Exhibiting Antiviral Resistance of HIV-1 RNA ≥200 Copies/mL at Week 49
ParticipantsPooled Treatment
Number of Participants From the Pooled Treatment Group Exhibiting Antiviral Resistance of HIV-1 RNA ≥200 Copies/mL at Week 497
SecondaryNumber of Participants From the Pooled Treatment Group Exhibiting Antiviral Resistance of HIV-1 RNA ≥200 Copies/mL at Week 97

The number of participants from the pooled treatment group exhibiting antiviral resistance of HIV-1 RNA ≥200 copies/mL at Week 97 is presented. .Analysis of the pooled treatment group was planned per protocol,

Time frame:
Week 97
Reported as:
Count of participants · Participants
Number of Participants From the Pooled Treatment Group Exhibiting Antiviral Resistance of HIV-1 RNA ≥200 Copies/mL at Week 97
ParticipantsPooled Treatment
Number of Participants From the Pooled Treatment Group Exhibiting Antiviral Resistance of HIV-1 RNA ≥200 Copies/mL at Week 975
SecondaryChange From Baseline Day 1 to Week 25 in Cluster of Differentiation 4+ (CD4+) T-cell Counts From the Pooled Treatment Group

The change from baseline Day 1 to Week 25 in CD4+ T-cell counts was determined by the central laboratory.. The within-group 95% CIs were calculated based on the t-distribution. Analysis of the pooled treatment group was planned per protocol,

Time frame:
Day 1 (baseline) and Week 25
Reported as:
Mean · cells/mm^3
Change From Baseline Day 1 to Week 25 in Cluster of Differentiation 4+ (CD4+) T-cell Counts From the Pooled Treatment Group
cells/mm^3Pooled Treatment
Change From Baseline Day 1 to Week 25 in Cluster of Differentiation 4+ (CD4+) T-cell Counts From the Pooled Treatment Group50.3 (27.8 to 72.9)
SecondaryChange From Baseline Day 1 to Week 49 in CD4+ T-cell Counts From the Pooled Treatment Group

The change from baseline Day 1 to Week 49 in CD4+ T-cell counts was determined by the central laboratory.. The within-group 95% CIs were calculated based on the t-distribution. Analysis of the pooled treatment group was planned per protocol,

Time frame:
Day 1 (baseline) and Week 49
Reported as:
Mean · cells/mm^3
Change From Baseline Day 1 to Week 49 in CD4+ T-cell Counts From the Pooled Treatment Group
cells/mm^3Pooled Treatment
Change From Baseline Day 1 to Week 49 in CD4+ T-cell Counts From the Pooled Treatment Group86.9 (51.2 to 122.5)
SecondaryChange From Baseline Day 1 to Week 97 in CD4+ T-cell Counts From the Pooled Treatment Group

The change from baseline Day 1 to Week 97 in CD4+ T-cell counts was determined by the central laboratory.. The within-group 95% CIs were calculated based on the t-distribution. Analysis of the pooled treatment group was planned per protocol,

Time frame:
Day 1 (baseline) and Week 97
Reported as:
Mean · cells/mm^3
Change From Baseline Day 1 to Week 97 in CD4+ T-cell Counts From the Pooled Treatment Group
cells/mm^3Pooled Treatment
Change From Baseline Day 1 to Week 97 in CD4+ T-cell Counts From the Pooled Treatment Group114.6 (54.7 to 174.6)
SecondaryChange From Baseline Day 8 to Week 25 in CD4+ T-cell Counts From the Pooled Treatment Group

The change from baseline Day 8 to Week 25 in CD4+ T-cell counts was determined by the central laboratory.. The within-group 95% CIs were calculated based on the t-distribution. Analysis of the pooled treatment group was planned per protocol,

Time frame:
Day 8 (baseline) and Week 25
Reported as:
Mean · cells/mm^3
Change From Baseline Day 8 to Week 25 in CD4+ T-cell Counts From the Pooled Treatment Group
cells/mm^3Pooled Treatment
Change From Baseline Day 8 to Week 25 in CD4+ T-cell Counts From the Pooled Treatment Group38.0 (9.6 to 66.4)
SecondaryChange From Baseline Day 8 to Week 49 in CD4+ T-cell Counts From the Pooled Treatment Group

The change from baseline Day 8 to Week 49 in CD4+ T-cell counts was determined by the central laboratory.. The within-group 95% CIs were calculated based on the t-distribution. Analysis of the pooled treatment group was planned per protocol,

Time frame:
Day 8 (baseline) and Week 49
Reported as:
Mean · cells/mm^3
Change From Baseline Day 8 to Week 49 in CD4+ T-cell Counts From the Pooled Treatment Group
cells/mm^3Pooled Treatment
Change From Baseline Day 8 to Week 49 in CD4+ T-cell Counts From the Pooled Treatment Group75.1 (36.9 to 113.4)
SecondaryChange From Baseline Day 8 to Week 97 in CD4+ T-cell Counts From the Pooled Treatment Group

The change from baseline Day 8 to Week 97 in CD4+ T-cell counts was determined by the central laboratory.. The within-group 95% CIs were calculated based on the t-distribution. Analysis of the pooled treatment group was planned per protocol,

Time frame:
Day 8 (baseline) and Week 97
Reported as:
Mean · cells/mm^3
Change From Baseline Day 8 to Week 97 in CD4+ T-cell Counts From the Pooled Treatment Group
cells/mm^3Pooled Treatment
Change From Baseline Day 8 to Week 97 in CD4+ T-cell Counts From the Pooled Treatment Group108.0 (47.9 to 168.2)

Adverse events

Collected over All-Cause Mortality (ACM): from randomization up to Week 49; Adverse Events (AE): from treatment ( Day 1) Up to Week 97. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
ISL+ART0/7 (0%)2/7 (28.6%)6/7 (85.7%)
DOR+ART0/14 (0%)2/14 (14.3%)14/14 (100%)
DOR/ISL+ART0/7 (0%)0/7 (0%)6/7 (85.7%)
Placebo+ART0/7 (0%)2/7 (28.6%)7/7 (100%)
Most frequent serious events
Most frequent serious events
EventISL+ARTDOR+ARTDOR/ISL+ARTPlacebo+ART
Angina pectorisCardiac disorders0/70/140/71/7
Colitis ulcerativeGastrointestinal disorders0/70/140/71/7
COVID-19 pneumoniaInfections and infestations1/70/140/70/7
SARS-CoV-2 sepsisInfections and infestations1/70/140/70/7
Lower limb fractureInjury, poisoning and procedural complications1/70/140/70/7
Reactive gastropathyInjury, poisoning and procedural complications0/70/140/71/7
COVID-19Infections and infestations0/71/140/70/7
Postoperative wound infectionInfections and infestations0/71/140/70/7
Castleman's diseaseNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/71/140/70/7
Most frequent other events
Showing 10 of 119
Most frequent other events
EventISL+ARTDOR+ARTDOR/ISL+ARTPlacebo+ART
Lymphocyte count decreasedInvestigations0/75/140/70/7
DiarrhoeaGastrointestinal disorders0/74/142/71/7
Chest painGeneral disorders1/71/141/72/7
COVID-19Infections and infestations1/74/140/72/7
Blood creatine phosphokinase increasedInvestigations0/71/142/71/7
Creatinine renal clearance decreasedInvestigations2/73/140/71/7
MyalgiaMusculoskeletal and connective tissue disorders0/70/140/72/7
AnaemiaBlood and lymphatic system disorders1/71/141/70/7
CataractEye disorders0/70/140/71/7
Eye allergyEye disorders0/70/140/71/7

Baseline characteristics

Age, Continuous
Age, Continuous(Years)ISL + ARTDOR + ARTDOR/ISL + ARTPlacebo + ARTTotal
Mean46.6 ± 12.748.6 ± 11.854.0 ± 10.044.6 ± 9.148.5 ± 11.1
Sex: Female, Male
Sex: Female, Male(Participants)ISL + ARTDOR + ARTDOR/ISL + ARTPlacebo + ARTTotal
Female24118
Male5106627
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)ISL + ARTDOR + ARTDOR/ISL + ARTPlacebo + ARTTotal
Hispanic or Latino02204
Not Hispanic or Latino7125731
Unknown or Not Reported00000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)ISL + ARTDOR + ARTDOR/ISL + ARTPlacebo + ARTTotal
American Indian or Alaska Native00000
Asian01012
Native Hawaiian or Other Pacific Islander00000
Black or African American550111
White276520
More than one race01102
Unknown or Not Reported00000
Plasma HIV-1 RNA
Plasma HIV-1 RNA(Log10 copies/mL)ISL + ARTDOR + ARTDOR/ISL + ARTPlacebo + ARTTotal
Mean4.1 ± 0.84.3 ± 0.94.5 ± 0.84.2 ± 0.74.3 ± 0.8
Custer of differentiation 4+ (CD4+) T-cell Count
Custer of differentiation 4+ (CD4+) T-cell Count(cells/mm^3)ISL + ARTDOR + ARTDOR/ISL + ARTPlacebo + ARTTotal
Mean166.3 ± 121.7132.4 ± 136.6178.6 ± 135.5132.6 ± 100.7148.5 ± 123.3
Genotypic resistance
Genotypic resistance(Participants)ISL + ARTDOR + ARTDOR/ISL + ARTPlacebo + ARTTotal
Nucleos(t)ide reverse transcriptase inhibitor (NRTI) substitutions7147735
Non-nucleoside reverse transcriptase inhibitor (NNRTI) substitutions7147735
Protease inhibitor (PI) substitutions7147735
Integrase strand transfer inhibitor (InSTI )substitutions595625
Phenotypic resistance
Phenotypic resistance(Participants)ISL + ARTDOR + ARTDOR/ISL + ARTPlacebo + ARTTotal
NRTI7147735
NNRTI6137733
PI7127632
InSTI595726
08

Study locations

98 sites
  • University of Alabama at Birmingham 1917 Research Clinic ( Site 4031)
    Birmingham, Alabama 35222, United States
  • Men's Health Foundation ( Site 4018)
    Los Angeles, California 90069, United States
  • Palmtree Clinical Research, Inc. ( Site 4016)
    Palm Springs, California 92262, United States
  • Yale School of Medicine ( Site 4007)
    New Haven, Connecticut 06510, United States
  • Georgetown University Hospital ( Site 4015)
    Washington, District of Columbia 20007, United States
  • The Kinder Medical Group ( Site 4014)
    Miami, Florida 33133, United States
  • Orlando Immunology Center ( Site 4012)
    Orlando, Florida 32803, United States
  • Triple O Research Institute, P.A. ( Site 4020)
    West Palm Beach, Florida 33407, United States
  • Chatham County Health Department ( Site 4029)
    Savannah, Georgia 31410, United States
  • Howard Brown Health Center ( Site 4006)
    Chicago, Illinois 60613, United States
  • Northstar Healthcare ( Site 4004)
    Chicago, Illinois 60657, United States
  • University of Maryland ( Site 4023)
    Baltimore, Maryland 21201, United States
  • The University of Mississippi Medical Center ( Site 4036)
    Jackson, Mississippi 39216, United States
  • Saint Michael's Medical Center-Research - Infectious Disease ( Site 4035)
    Newark, New Jersey 07102, United States
  • Icahn School of Medicine at Mount Sinai ( Site 4000)
    New York, New York 10029, United States
  • University of North Carolina at Chapel Hill ( Site 4026)
    Chapel Hill, North Carolina 27599, United States
  • Saint Hope Foundation, Inc. ( Site 4034)
    Bellaire, Texas 77401, United States
  • North Texas Infectious Diseases Consultants, PA ( Site 4005)
    Dallas, Texas 75246, United States
  • Dr. Peter Shalit, MD ( Site 4002)
    Seattle, Washington 98104, United States
  • Holdsworth House Medical Practice ( Site 5300)
    Sydney, New South Wales 2000, Australia
  • St Vincent's Hospital ( Site 5309)
    Sydney, New South Wales 2010, Australia
  • Holdsworth House Medical Practice - Brisbane ( Site 5312)
    Brisbane, Queensland 4006, Australia
  • Monash Health-Monash Medical Centre ( Site 5313)
    Clayton, Victoria 3168, Australia
  • The Alfred Hospital ( Site 5304)
    Melbourne, Victoria 3004, Australia
  • Vancouver ID Research and Care Centre Society ( Site 4100)
    Vancouver, British Columbia V6Z 2C7, Canada
  • Hamilton Health Sciences ( Site 4115)
    Hamilton, Ontario L8L 2X2, Canada
  • Ottawa Hospital Research Institute ( Site 4111)
    Ottawa, Ontario K1H 8L6, Canada
  • Toronto General Hospital - University Health Network ( Site 4105)
    Toronto, Ontario M5G 2N2, Canada
  • McGill University Health Center - Research Institute-CVIS Clinical Research Unit ( Site 4102)
    Montreal, Quebec H4A 3J1, Canada
  • Hospital Dr. Hernan Henriquez Aravena ( Site 4405)
    Temuco, Araucania 4781151, Chile
  • Fundacion Arriaran ( Site 4401)
    Santiago, Region M. De Santiago 8360159, Chile
  • Centro Cardiovascular Cardiosur ( Site 4407)
    Santiago, Region M. De Santiago 8910259, Chile
  • Clinica Colsanitas S.A. Sede Clinica Universitaria Colombia ( Site 4306)
    Bogota, Distrito Capital De Bogota 111321, Colombia
  • Fundacion Valle del Lili ( Site 4301)
    Cali, Valle Del Cauca 760032, Colombia
  • Hopital Edouard Herriot ( Site 4726)
    Lyon, Ain 69003, France
  • A.P.H. Paris. Hopital Bichat Claude Bernard ( Site 4724)
    Paris, Ain 75018, France
  • CHU de Nice Hopital Archet 1 ( Site 4703)
    Nice, Alpes-Maritimes 06202, France
  • Hopital Europeen Marseille ( Site 4717)
    Marseille, Bouches-du-Rhone 13003, France
  • CHU de Bordeaux- Hopital Saint Andre ( Site 4715)
    Bordeaux, Gironde 33075, France
  • CHU de Rouen ( Site 4705)
    Rouen, Haute-Normandie 76031, France
  • CHU de Montpellier - Hopital Saint-Eloi ( Site 4721)
    Montpellier, Herault 34295, France
  • Centre Hospitalier de Tourcoing ( Site 4700)
    Tourcoing, Nord 59208, France
  • Hopital Avicenne ( Site 4702)
    Bobigny, Seine-Saint-Denis 93000, France
  • Hopital Hotel Dieu [Paris, France] ( Site 4723)
    Paris, 75004, France
  • A.P.H. Paris, Hopital Saint Louis ( Site 4714)
    Paris, 75010, France
  • Medizinische Hochschule Hannover ( Site 4612)
    Hannover, Niedersachsen 30625, Germany
  • Universitaetsklinikum Bonn ( Site 4600)
    Bonn, Nordrhein-Westfalen 53127, Germany
  • Universitaetsklinikum Essen ( Site 4607)
    Essen, Nordrhein-Westfalen 45122, Germany
  • ZIBP-Zentrum fur Infektiologie Berlin Prenzlauer Berg GmbH ( Site 4603)
    Berlin, 10439, Germany
  • EPIMED GmbH ( Site 4608)
    Berlin, 10787, Germany
  • ICH Study Center GmbH & Co.KG ( Site 4609)
    Hamburg, 20146, Germany
  • Azienda Ospedaliero Universitaria di Modena Policlinico ( Site 5004)
    Modena, Emilia-Romagna 41124, Italy
  • Ospedale San Gerardo ASST Monza ( Site 5012)
    Monza, Monza E Brianza 20900, Italy
  • Fondazione IRCCS Ca' Granda-Ospedale Maggiore Policlinico ( Site 5001)
    Milano, 20122, Italy
  • Universita' Vita Salute. Ospedale San Raffaele ( Site 5002)
    Milano, 20127, Italy
  • Azienda Ospedaliera San Paolo ( Site 5003)
    Milano, 20142, Italy
  • ASST Fatebenefratelli-Ospedale Sacco ( Site 5000)
    Milano, 20157, Italy
  • IRCCS Policlinico San Matteo ( Site 5010)
    Pavia, 27100, Italy
  • Istituto Nazionale per Le Malattie Infettive Lazzaro Spallanzani ( Site 5005)
    Roma, 00149, Italy
  • Policlinico Gemelli Instituto di Clinica Chirurgica ( Site 5006)
    Roma, 00168, Italy
  • Center Hospital of the National Center for Global Health and Medicine ( Site 5401)
    Tokyo, 162-8655, Japan
  • Pusan National University Hospital ( Site 5503)
    Busan, Pusan-Kwangyokshi 49241, Korea, Republic of
  • Severance Hospital Yonsei University Health System ( Site 5500)
    Seoul, 03722, Korea, Republic of
  • The Catholic University of Korea. Seoul St. Mary s Hospital ( Site 5502)
    Seoul, 06591, Korea, Republic of
  • INMENSA ( Site 4506)
    Lima, Muni Metro De Lima 15046, Peru
  • Via Libre ( Site 4500)
    Lima, 15001, Peru
  • Policlinico Universidad Nacional Mayor de San Marcos ( Site 4501)
    Lima, 15081, Peru
  • Hospital de Nossa Senhora da Oliveira- EPE ( Site 4905)
    Guimaraes, Braga 4835-044, Portugal
  • Hospital Dr. Fernando Fonseca, EPE - Amadora/Sintra ( Site 4902)
    Amadora, Lisboa 2720-276, Portugal
  • Centro Hospitalar de Lisboa Norte Hospital de Santa Maria ( Site 4913)
    Lisboa, 1649-035, Portugal
  • Hospital Geral de Santo Antonio ( Site 4908)
    Porto, 4099-001, Portugal
  • Centro Hospitalar de Sao Joao. EPE - Hospital de Sao Joao ( Site 4907)
    Porto, 4200-319, Portugal
  • HOPE Clinical Research ( Site 5700)
    San Juan, 00909, Puerto Rico
  • Saint Petersburg Center for Prophylactic of AIDS and Inf. Diseases ( Site 5101)
    Saint Petersburg, Leningradskaya Oblast, Russian Federation
  • Infectious Clinical Hospital #2 ( Site 5114)
    Moscow, Moskva 105275, Russian Federation
  • Gbuz Samarskiy Oblastnoy Klinicheskiy Tsentr Profilaktiki I Bor'by So Spid ( Site 5113)
    Samara, Samarskaya Oblast 443124, Russian Federation
  • FGU Republican Clinical Infectious Hospital of Roszdrav ( Site 5100)
    Saint Petersburg, Sankt-Peterburg 196645, Russian Federation
  • Smolensk Center On Aids And Infectious Diseases Prophylaxis ( Site 5115)
    Smolensk, Smolenskaya Oblast 214006, Russian Federation
  • Regional Center for Prevent. and Control of AIDS and Inf. Diseases ( Site 5106)
    Yekaterinburg, Sverdlovskaya Oblast 620102, Russian Federation
  • Republican Clinical Hospital of Infectious Diseases n. a. A.F.Agafonov ( Site 5104)
    Kazan, Tatarstan, Respublika 420140, Russian Federation
  • FARMOVS ( Site 4805)
    Bloemfontein, Free State 9301, South Africa
  • Wits Clinical HIV Research Unit ( Site 4804)
    Johannesburg, Gauteng 2041, South Africa
  • Ezintsha ( Site 4806)
    Johannesburg, Gauteng 2193, South Africa
  • King Edward Hospital ( Site 4802)
    Durban, Kwazulu-Natal 4013, South Africa
  • Hospital Universitari Germans Trias i Pujol ( Site 5600)
    Badalona, Barcelona 08916, Spain
  • Hospital Clinic i Provincial ( Site 5601)
    Barcelona, Cataluna 08036, Spain
  • Hospital Santa Lucia ( Site 5603)
    Cartagena, Murcia, Region De 30202, Spain
  • Hospital Universitario La Paz ( Site 5604)
    Madrid, 28046, Spain
  • Dnipropetrovsk Regional Center of Socially Significant Diseases ( Site 5619)
    Dnipro, Dnipropetrovska Oblast 49115, Ukraine
  • Regional Clinical Infectious Hospital ( Site 5614)
    Kharkiv, Kharkivska Oblast 61096, Ukraine
  • Kherson City Clinical Hospital n.a. Y.Y. Karabelesh ( Site 5620)
    Kherson, Khersonska Oblast 73000, Ukraine
  • Institute of Epidemiology and Infect Diseases of the NAMS of Ukraine ( Site 5615)
    Kyiv, Kyivska Oblast 03038, Ukraine
  • Mykolaiv center of paliative assistance and integrated services ( Site 5621)
    Mykolaiv, Mykolaivska Oblast 54003, Ukraine
  • MNE Odesa Regional Center of Socially Significant Diseases ( Site 5611)
    Odesa, Odeska Oblast 65014, Ukraine
  • MI Vinnytsia Regional Center of AIDS Prevention and Care ( Site 5618)
    Berezina, Vinnytska Oblast 23222, Ukraine
  • Kyiv City Clinical Hospital 5 ( Site 5616)
    Kyiv, 03115, Ukraine
  • Royal Free Hospital ( Site 5202)
    London, Camden NW3 2QG, United Kingdom
  • Western General Hospital ( Site 5201)
    Edinburgh, Edinburgh, City Of EH4 2XU, United Kingdom
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · engagezone.msd.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2020 to primary completion in Nov 2022, 32 months.

Results were first posted in Dec 2023, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 15, 2020
First posted
Jan 18, 2020
StartActual
Mar 18, 2020
Primary completionActual
Nov 21, 2022
CompletionActual
Nov 1, 2023
Results first posted
Dec 8, 2023
Last update
Dec 27, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 27, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04233216
Responsible party
Sponsor
First posted
Jan 18, 2020
Start date
Mar 18, 2020
Primary completion
Nov 21, 2022
Completion
Nov 1, 2023
Results posted
Dec 8, 2023
Last update
Dec 27, 2024

Study contacts

Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Islatravir · Doravirine

Start the discussion